Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Donepezil Clear all
Completed Phase 2 Interventional

Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

NCT00070161
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Radiation Toxicity
Interventions
EGb761, donepezil hydrochloride, cognitive assessment
Dietary Supplement · Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
4
States / cities
Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

NCT00408525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donepezil
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jun 7, 2026, 9:32 AM EDT
Withdrawn Phase 1 Interventional

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

NCT03316898
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AGN-242071, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Allergan
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

NCT00916383
View directory record Official record
Conditions
Irritation/Irritant
Interventions
350 mg Donepezil Transdermal Patch, Placebo Patch
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Phoenix, Arizona • Fresno, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 7, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional Results available

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101 35 mg tablets
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 86 Years
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Jun 7, 2026, 9:32 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Donepezil on Smoking

NCT01250977
View directory record Official record
Conditions
Smoking
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

NCT00934375
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aricept (donepezil hydrochloride), placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
145 participants
Timeline
2006 – 2007
U.S. locations
49
States / cities
Alabaster, Alabama • Peoria, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

NCT02055703
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, itraconazole, rifampin, digoxin, donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Jun 7, 2026, 9:32 AM EDT
Active, not recruiting Early Phase 1 Interventional

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

NCT05438264
View directory record Official record
Conditions
Bilateral Sensorineural Hearing Loss
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

NCT00483028
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donezepil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Haven, Connecticut • Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2008 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

NCT00018278
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Aricept, Exelon, Nicoderm Patch
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Usability (TADU)

NCT04731311
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
Device
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

NCT01260922
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Use of Donepezil for Treatment of Cocaine Dependence

NCT00467389
View directory record Official record
Conditions
Cocaine Abuse and Dependence
Interventions
Donepezil, 5 mg daily, Oral Placebo
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 7, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

NCT00675025
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jun 7, 2026, 9:32 AM EDT
Not yet recruiting Phase 2 Interventional

An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa

NCT06518941
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02406261
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Simvastatin, Midazolam, Donepezil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

NCT00293176
View directory record Official record
Conditions
Memory Loss
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
54
States / cities
Albaster, Alabama • Mesa, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Jun 7, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study With Aricept® (Donepezil)

NCT01042314
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jun 7, 2026, 9:32 AM EDT